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“I think that the Septin 9 
blood test is very convenient 
in between the 10-year 
colonoscopy.” (Screened)
“I like it because it can 
replace the need for 
colonoscopy.”
(Screened)
 64% selected Septin 9 
as their first choice.
 30% selected 
colonoscopy as their 
first choice.
 There were no 
significant differences 
in participants’ first 
choice based            





Figure 1. Participants’ beliefs 
about CRC screening strategies
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Introduction
 Colorectal or colon cancer (CRC) is the second most 
commonly diagnosed cancer in both men and women            
in the U.S. (Jemal et al., 2009).
 Although screening decreases CRC incidence (Burt, 2010) and 
mortality, currently, less than 50% of the eligible population 
undergoes regular CRC screening (American Cancer Society, 2010). 
 The advent of biomarker technologies such as a blood-based 
CRC screening test (Septin 9 blood test; ARUP Laboratories, 2010) may 
increase CRC screening by decreasing barriers currently 
contributing to health disparities. 
 Septin 9, a new blood-based biomarker CRC screening test, 
detects methylated Septin 9 DNA with 90% sensitivity and 
89% specificity. This test requires no preparation and is 
recommended to occur every 1-2 years. Septin 9’s ability to 
detect precancerous polyps is undetermined, and the test is 
not intended to replace colonoscopy. 
 This study is the first to assess patient beliefs about         




 Design: We are in the process of recruiting 120 adults           
to participate in a series of focus groups stratified           
by Race/Ethnicity (White, Black or African American,          
and Hispanic or Latino/a) and Screening Status (previously 
screened, never screened).
 Quantitative and qualitative data are collected through 
group discussion and pre- and post-questionnaires. 
 Participants are given information about 4 tests: 
Colonoscopy, sigmoidoscopy, FOBT, and Septin 9. 
 Participants (all at population risk for CRC): 
• n = 50; 42% male
• Aged 48 to 73 (M = 59, SD = 7.67)
• 74% Caucasian; 12% African American; 6% Hispanic
• 54% previously screened for CRC
• 84% currently have healthcare coverage
• Median income is $40-$49K
Future Research
Table 1. Factors that participants 
like about the Septin 9 test*
Any positive 82%
Procedure (convenience, simplicity, comfort, 





Ability to increase screening rates 6%
Table 2. Factors that participants 
do not like about the Septin 9 test*
Any negative 32%
More research needs to be done 14%
Inability to detect precancerous growths 10%
Higher cost 6%
Potential lack of insurance coverage 6%
Possibility of false positives 2%
Frequency (too often) 2%
 This study is the first in a series. We plan to conduct 3 additional 
phases: 
1. Focus groups will be conducted with primary care physicians    
from multiple settings to assess physician interest in and 
willingness to recommend the Septin 9 blood test to patients. 
2. Information from the initial patient focus groups will be used  
to design  a quantitative survey to assess patients’ preferences                   
and perceived barriers and benefits of CRC screening. 
3. Finally, we will assess differential predictors of Septin 9            
and colonoscopy uptake by offering screening in a prospective 
longitudinal study. 
“I would say do the Septin 9 and if 
I got a positive result I would 
schedule the colonoscopy. This 
test could lead me to do a 
colonoscopy.” (Unscreened)
Figure 2. Decision tree of participants’ prediction of first           
and second screening choice stratified by screening status 
“You have to have a really 
good reason before I give up 
colonoscopy because of its 
high accuracy.“ (Screened)
 The majority of participants listed advantages of the Septin 9 
test such as convenient, noninvasive aspects of the procedure 
and high accuracy, while only one-third listed disadvantages     
such as the need for more research and the test’s inability        
to detect precancerous polyps. 
 The majority of participants, regardless of screening status, 
selected the Septin 9 test as their first choice for future CRC 
screening. 
 However, participants spontaneously considered a wide variety 
of screening strategies which included various combinations    
of having the Septin 9 test and/or colonoscopies in the future.
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*Taken from the open-ended items on the post-discussion questionnaire
“To me Septin 9 sounds like a 
great place to start. It’s pretty 
easy other than the poke of a 
needle. It’ll help direct you for 
further need or you won’t have 
to worry about it for a while.”
(Unscreened)
“If you come out of your blood 
test and it’s a false positive, 
you’re like, “Oh shoot, holy 
smokes!” A colonoscopy 
doesn’t have that risk.”
(Unscreened)
Septin 9 & Colonoscopy
Septin 9 onlyColonoscopy only
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